Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease , during the outbreak of the coronavirus disease , in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake
A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced Monday if not sooner, the Journal said, citing people familiar with the matter.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
Read more »
WSJ News Exclusive | Gilead Nears Deal to Buy Immunomedics for More Than $20 BillionGilead Sciences is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion, according to people familiar with the matter.
Read more »
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
Read more »
WSJ News Exclusive | Gilead Nears Deal to Buy Immunomedics for More Than $20 BillionGilead Sciences is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion, according to people familiar with the matter.
Read more »
Nvidia nears deal to buy chip designer Arm for more than $40 billion - sourcesNvidia Corp is close to a deal to buy British chip designer Arm Holdings from SoftBank Group Corp for more than $40 billion in a deal which would create a giant in the chip industry, according to two people familiar with the matter.
Read more »
Nvidia nears deal to buy chip designer Arm for more than $40 billion - sourcesNvidia Corp is close to a deal to buy British chip designer Arm Holdings from SoftBank Group Corp for more than $40 billion in a deal which would create a giant in the chip industry, according to two people familiar with the matter.
Read more »